Pedro Cabrales1, Scott Caroen2, Arnold Oronsky3, Corey Carter4, Jane Trepel5, Thomas Summers4, Tony Reid6, Neil Oronsky6, Michelle Lybeck2, Bryan Oronsky2. 1. a Department of Bioengineering , University of California San Diego (UCSD) , La Jolla , CA , USA. 2. b EpicentRx , Mountain View , CA , USA. 3. c InterWest Partners , Menlo Park , CA , USA. 4. d Walter Reed Military Medical Center , Murtha Cancer Center , Bethesda , MD , USA. 5. e Moores Cancer Center , University of California San Diego (UCSD) , La Jolla , CA , USA. 6. f CFLS Data , San Jose , CA , USA.
Abstract
BACKGROUND: RRx-001, a clinical macrophage-stimulating anti-cancer agent that also produces nitric oxide (NO) was studied in a model of ischemia-reperfusion injury. METHODS: The production of NO is dependent on the oxygen tension because nitric oxide synthases convert l-arginine to NO and l-citrulline in the presence of O2. Since the P450 enzymes, which metabolize nitrate esters such as nitroglycerin are dependent on oxygen, the generation of 'exogenous' NO is also sensitive to alterations in tissue PO2. I/R injury was studied in a hamster chamber window, with compression of the periphery of the window for 1 h to induce ischemia. Animals received RRx-001 (5 mg/kg) 24 h before ischemia and sodium nitrite (10 nmols/kg) was supplemented 10 min after the start of reperfusion. Vessel diameter, blood flow, adherent leukocytes, and functional capillary density were assessed by intravital microscopy at 0.5, 2, and 24 h following the release of the ischemia. RESULTS: The results demonstrated that, compared to control, RRx-001 preconditioning increased blood flow and functional capillary density, and preserved tissue viability in the absence of side effects over a sustained time period. CONCLUSION: Thus, RRx-001 may serve as a long-lived protective agent during postsurgical restoration of flow and other ischemia-reperfusion associated conditions, increasing blood flow and functional capillary density as well as preserving tissue viability in the absence of side effects.
BACKGROUND:RRx-001, a clinical macrophage-stimulating anti-cancer agent that also produces nitric oxide (NO) was studied in a model of ischemia-reperfusion injury. METHODS: The production of NO is dependent on the oxygen tension because nitric oxide synthases convert l-arginine to NO and l-citrulline in the presence of O2. Since the P450 enzymes, which metabolize nitrate esters such as nitroglycerin are dependent on oxygen, the generation of 'exogenous' NO is also sensitive to alterations in tissue PO2. I/R injury was studied in a hamster chamber window, with compression of the periphery of the window for 1 h to induce ischemia. Animals received RRx-001 (5 mg/kg) 24 h before ischemia and sodium nitrite (10 nmols/kg) was supplemented 10 min after the start of reperfusion. Vessel diameter, blood flow, adherent leukocytes, and functional capillary density were assessed by intravital microscopy at 0.5, 2, and 24 h following the release of the ischemia. RESULTS: The results demonstrated that, compared to control, RRx-001 preconditioning increased blood flow and functional capillary density, and preserved tissue viability in the absence of side effects over a sustained time period. CONCLUSION: Thus, RRx-001 may serve as a long-lived protective agent during postsurgical restoration of flow and other ischemia-reperfusion associated conditions, increasing blood flow and functional capillary density as well as preserving tissue viability in the absence of side effects.
Authors: Mark T Gladwin; Nicolaas J H Raat; Sruti Shiva; Cameron Dezfulian; Neil Hogg; Daniel B Kim-Shapiro; Rakesh P Patel Journal: Am J Physiol Heart Circ Physiol Date: 2006-06-23 Impact factor: 4.733
Authors: Bryan Oronsky; Jan Scicinski; Shoucheng Ning; Donna Peehl; Arnold Oronsky; Pedro Cabrales; Mark Bednarski; Susan Knox Journal: Invest New Drugs Date: 2016-02-03 Impact factor: 3.850
Authors: Kimberly J Jurgensen; William K J Skinner; Bryan Oronsky; Nacer D Abrouk; Andrew E Graff; Reid D Landes; William E Culp; Thomas A Summers; Lynnette H Cary Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810